Akebia dives following safety concerns for lead drug in Phase IIb
This article was originally published in Scrip
Executive Summary
Akebia Therapeutics' stock has plummeted after the company disclosed one "possibly drug-related" death, and two other patient deaths, in a Phase IIb trial of its lead product AKB-6548.